UNISEC

Universal Influenza Vaccines Secured

 Coordinatore RIJKSUNIVERSITEIT GRONINGEN 

 Organization address address: Broerstraat 5
city: GRONINGEN
postcode: 9712CP

contact info
Titolo: Dr.
Nome: Dick
Cognome: Veldhuis
Email: send email
Telefono: +31 503634142
Fax: +31 503634181

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 7˙824˙314 €
 EC contributo 5˙972˙180 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    RIJKSUNIVERSITEIT GRONINGEN

 Organization address address: Broerstraat 5
city: GRONINGEN
postcode: 9712CP

contact info
Titolo: Dr.
Nome: Dick
Cognome: Veldhuis
Email: send email
Telefono: +31 503634142
Fax: +31 503634181

NL (GRONINGEN) coordinator 1˙264˙250.80
2    PEPTCELL LTD

 Organization address address: Fetter Lane 100
city: LONDON
postcode: EC4A 1BN

contact info
Titolo: Mr.
Nome: Gregory
Cognome: Stoloff
Email: send email
Telefono: 442072000000
Fax: 442072000000

UK (LONDON) participant 658˙200.00
3    BIONDVAX PHARMACEUTICALS LTD

 Organization address address: EINSTEIN STREET 14
city: NES ZIONA
postcode: 74036

contact info
Titolo: Dr.
Nome: Tanya
Cognome: Gottlieb
Email: send email
Telefono: +972 89302529

IL (NES ZIONA) participant 536˙349.00
4    ACADEMISCH ZIEKENHUIS GRONINGEN

 Organization address address: Hanzeplein 1
city: GRONINGEN
postcode: 9713 GZ

contact info
Titolo: Mrs.
Nome: Johanna M
Cognome: Van Apeldoorn
Email: send email
Telefono: 31503633040

NL (GRONINGEN) participant 524˙400.00
5    STATENS SERUM INSTITUT

 Organization address address: ARTILLERIVEJ 5
city: KOBENHAVN S
postcode: 2300

contact info
Titolo: Dr.
Nome: Dennis
Cognome: Christensen
Email: send email
Telefono: +45 32683804
Fax: +45 32683035

DK (KOBENHAVN S) participant 524˙400.00
6    ROBERT KOCH-INSTITUT

 Organization address address: Nordufer 20
city: Berlin
postcode: 13353

contact info
Titolo: Mrs.
Nome: Birgit
Cognome: Arnold
Email: send email
Telefono: +49 30187542680
Fax: +49 30 18754 2631

DE (Berlin) participant 416˙600.40
7    Department of Health

 Organization address address: "Quarry House, Quarry Hill"
city: Leeds
postcode: LS2 7UE

contact info
Titolo: Ms.
Nome: Amanda
Cognome: King
Email: send email
Telefono: +44 01707641352

UK (Leeds) participant 386˙964.75
8    Nome Ente NON disponibile

 Organization address address: ALBERT FLORIAN UTCA 2-6
city: Budapest
postcode: 1097

contact info
Titolo: Dr.
Nome: Ildiko
Cognome: Visontai
Email: send email
Telefono: +36 14761383
Fax: +36 14761223

HU (Budapest) participant 363˙399.75
9    GOETEBORGS UNIVERSITET

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Dr.
Nome: Ellen
Cognome: Rydberg
Email: send email
Telefono: +46 31 786 6470
Fax: +46 31 786 4355

SE (GOETEBORG) participant 363˙200.40
10    NOVAVAX AB

 Organization address address: KUNGSGATAN 109
city: UPPSALA
postcode: 753 18

contact info
Titolo: Mr.
Nome: Erik
Cognome: Bergman
Email: send email
Telefono: +46 18161700
Fax: +46 181601

SE (UPPSALA) participant 323˙023.80
11    NASJONALT FOLKEHELSEINSTITUTT

 Organization address address: Lovisenberggata 8
city: OSLO
postcode: 403

contact info
Titolo: Mrs.
Nome: Kjerstin
Cognome: Klevdal Nielsen
Email: send email
Telefono: +47 21076264
Fax: +47 21077012

NO (OSLO) participant 321˙991.20
12    RETROSCREEN VIROLOGY LTD

 Organization address address: NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42
city: LONDON
postcode: E1 2AX

contact info
Titolo: Prof.
Nome: John
Cognome: Oxford
Email: send email
Telefono: +44 2071536573
Fax: +44 2030700086

UK (LONDON) participant 289˙400.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

universal    expertise    influenza    site    clinical    evaluation    unisec    head    vaccine    trial    promising   

 Obiettivo del progetto (Objective)

'UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 4 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of scientific and technological expertise from lead identification to clinical trial execution.

UNISEC will bring a number of vaccine concepts together into a single study in order to identify, develop and clinically test the 3 most promising leads for a universal influenza vaccine, which must (1) demonstrate adequate (universal) protection, and (2) be technically suitable for development to a marketable product.

Preclinical and clinical methodologies will be developed allowing a comparative evaluation of the vaccine concepts. Head-to-head comparisons in animal models will also be performed, with the most promising concepts to then be ready for clinical assessment. Independent comparative clinical studies will be executed and carried out by 5 established Clinical Trial Site partners.

The expected impact of the UNISEC work programme will be the resolution of current problems of non-uniformity in the development and evaluation of universal influenza vaccines in Europe by a unified approach using an expert and sustainable vaccine expertise network. The UNISEC results will directly contribute to a timely, longer-term, broader, more effective and cost-effective universal influenza vaccine for the prevention of annual and pandemic influenza.

The success of UNISEC will be based on the leading experience of its consortium partners; the proven track record of its clinical trial site partners; and a coherent and well-defined management structure and dissemination program, underpinned by the fact that several UNISEC partners were previously part of the successful EU FLUSECURE project.'

Altri progetti dello stesso programma (FP7-HEALTH)

TEMPEST (2009)

Temptations to Eat Moderated by Personal and Environmental Self-regulation Tools

Read More  

AIM-HIV (2012)

"Hydroxitirosol, a new generation of microbicides targeting HIV through antiviral and anti-inflammatory pathways"

Read More  

TARGETAMD (2012)

"Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)"

Read More